Discontinuation rate and serious adverse events of chemoimmunotherapy as neoadjuvant treatment for triple-negative breast cancer: a systematic review and meta-analysis
- Resource Type
- Article
- Source
- In
ESMO Open December 2023 8(6) - Subject
Breast Cancer - Language
- ISSN
- 2059-7029